Successfully completed a Phase 1 dose-escalation study demonstrating pan-mutant clinical activity, 95% target engagement and no grade 3 or 4...
MIAMI, Jan. 10, 2025 (GLOBE NEWSWIRE) -- RESTEM – a clinical-stage biotechnology company that develops off-the-shelf, next-generation cell therapies designed...
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target...
By adding Canada and the entire Latin America region, including Mexico, WODA completes its full global commercialization offering for rare...
COPENHAGEN, Denmark, January 10, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™...
8th Sachs Annual Neuroscience Innovation Forum14th Annual LifeSci Advisors Corporate Access EventInvest Securities BioMed Forum 2025MidCap Events Frankfurt 2025Bio-Neuroscience 2025...
Preliminary unaudited fourth quarter 2024 net revenue expected to be approximately $12 million to $12.3 million, representing 99% growth over...
Prioritizing VTP-1000 development in celiac disease, Phase 1 data expected in mid-2025Postponing further clinical development of VTP-300 in chronic hepatitis...
Across all DME patients dosed to date, 4D-150 continues to be well tolerated with no intraocular inflammation observed at any...
SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Recludix Pharma, a leader in the discovery of inhibitors of challenging targets...
LONDON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing inhaled opelconazole for patients...
Strategically focused pipeline optimizes resource allocation to progress two product candidates with strongest clinical proof of concept: 4D-150 for wet...
High-volume, breakthrough radioisotope production platform to enable innovation in life sciences and industrial applicationsVALENCIA, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE)...
Private placement to radiopharmaceutical industry leader Lantheus, for US$5.0 millionPlacement at A$0.060 per share, representing a premium of 150% to...
ALACHUA, Fla. and TAMPA, Fla., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing...
- Positive interim results in infants and young children with ENPP1 Deficiency showed improvements from baseline in multiple measures of...
Seasoned biotechnology industry leadership spanning three decades across U.S. and global commercial operationsBRISBANE, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) --...
NEW YORK, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology...
Company also reports preliminary unaudited 2024 revenue of $701.0 millionPARSIPPANY, N.J., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc....
Publication reports 100% of participants were either “Much Improved” or “Very Much Improved” as rated by the Clinician Global Impression...